Using ultrasound to guide diuretic therapy for patients with Type 1 cardiorenal syndrome
Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome
This study tests if using ultrasound to guide diuretic treatment can help patients with Type 1 cardiorenal syndrome feel better and get out of the hospital faster.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Sex | All |
| Sponsor | Instituto Nacional de Cardiologia Ignacio Chavez Academic / other |
| Locations | 1 site (Mexico City) |
| Trial ID | NCT06065163 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of ultrasound-guided diuretic therapy in patients with Type 1 cardiorenal syndrome. It is a double-blind, randomized, controlled trial aimed at determining if patients can achieve faster decongestion within a maximum of 7 days during their hospital stay. The study will also assess changes in serum creatinine levels, NT-proBNP at discharge, diuretic adjustments, rates of hospital readmission, and 30-day mortality. The intervention involves adjusting diuretic therapy based on ultrasound findings and clinical assessments.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with Type 1 cardiorenal syndrome who are admitted to the emergency room.
Not a fit: Patients with liver disease, complex congenital heart disease, or those who have undergone kidney or heart transplants may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved management of fluid overload in patients with Type 1 cardiorenal syndrome, potentially reducing hospital stays and improving outcomes.
How similar studies have performed: While the specific approach of using ultrasound for diuretic therapy in this context is novel, similar studies have shown promise in improving patient outcomes in related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old or older * Type 1 cardiorenal syndrome in emergency room at Instituto Nacional de Cardiologia Ignacio Chávez Exclusion Criteria: * Patients who denied to participate * Liver disease (cirrohsis) * Complex congenital heart disease * Kidney transplant * Heart transplant * Severe valvular disease * Chronic kidney disease KDIGO G5 and G5d * INTERMACS Score 2
Where this trial is running
Mexico City
- Instituto Nacional de Cardiología Ignacio Chávez — Mexico City, Mexico (Recruiting)
Study contacts
- Study coordinator: Salvador López Gil, MD
- Email: salvadorlgil@gmail.com
- Phone: 5555732911
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.